Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 107 citing articles:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 131
Acute graft-versus-host disease
Florent Malard, Ernst Holler, Brenda M. Sandmaier, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 109
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients
Małgorzata Mikulska, Chiara Sepulcri, Chiara Dentone, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 2, pp. 280-286
Open Access | Times Cited: 99
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 89
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2022) Vol. 140, Iss. 26, pp. 2773-2787
Open Access | Times Cited: 73
Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 65
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 40
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders
Małgorzata Mikulska, Diletta Testi, Chiara Russo, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 4, pp. 628-639
Open Access | Times Cited: 31
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 30
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 28
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Jon Salmanton‐García, Francesco Marchesi, María Gomes da Silva, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101939-101939
Open Access | Times Cited: 27
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic
Linda Petrone, Alessandro Sette, Rory D. de Vries, et al.
Pathogens (2023) Vol. 12, Iss. 7, pp. 862-862
Open Access | Times Cited: 27
Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Małgorzata Mikulska, Hans H. Hirsch, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1933-1938
Open Access | Times Cited: 27
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 14
Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre–Cellular Therapy SARS-CoV-2 Infection
Ila Nimgaonkar, Leah H Yoke, Pavitra Roychoudhury, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 86-95
Closed Access | Times Cited: 10
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study
Jorge Calderón‐Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107095-107095
Open Access | Times Cited: 9
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults
Saskia Bos, John Murray, Monia Marchetti, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 3, pp. 2301727-2301727
Open Access | Times Cited: 9
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Jon Salmanton‐García, Francesco Marchesi, Andreas Glenthøj, et al.
HemaSphere (2022) Vol. 6, Iss. 11, pp. e789-e789
Open Access | Times Cited: 33
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 7
The unique presentation of SARS-CoV-2 Infection in patients with B-cell depletion: definition of ‘persistent inflammatory sero-negative COVID’
Ana Belkin, Avshalom Leibowitz, Liat Shargian, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 1, pp. 1-3
Open Access | Times Cited: 28
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy
María Stefania Infante, David Nemirovsky, Sean M. Devlin, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 116.e1-116.e12
Open Access | Times Cited: 14
A Machine Learning approach to identify groups of patients with hematological malignant disorders
Pablo Rodríguez-Belenguer, José Luís Piñana, Manuel Sánchez-Montañés, et al.
Computer Methods and Programs in Biomedicine (2024) Vol. 246, pp. 108011-108011
Open Access | Times Cited: 5
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 4
Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights
Heng Joo Ng, Maaz Kamal Alata, Quang The Nguyen, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top